Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CL-NK-001 in advanced pancreatic cancer
NCT06816823Phase 1Recruiting
- Sponsor
- Changhai Hospital
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CL-NK-001 in pancreatic cancer (PC), sponsored by Changhai Hospital. Primary endpoints: Dose-limiting toxicity at 42 days, Maximum tolerated dose at 42 days and 4 more. Started Apr 2025; status: recruiting.
02
Drugs
CL-NK-001
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06816823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816823.